Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884370 | 0.87 | TSHR (0.42) | HTR2CRYR2TSHRPNMTCD44 | |
| SCHEMBL9118595 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL2928 | 0.76 | — | — | |
| SCHEMBL7280713 | 0.74 | RYR2 (0.33) | RYR2ALDH1A1 | |
| SCHEMBL832046 | 0.68 | RYR2 (0.53) | HTR2CRYR2PNMTCD44MAOB | |
| SCHEMBL7281042 | 0.68 | MEN1 (0.41) | RYR2ALDH1A1HPGD | |
| SCHEMBL4488551 | 0.67 | ALDH1A1 (0.50) | HTR2CRYR2TSHRKDM4EALDH1A1 | |
| SCHEMBL1592642 | 0.64 | ITGB2 (0.44) | TSHR | |
| SCHEMBL9116473 | 0.64 | MAOA (0.35) | TSHRMAOB | |
| SCHEMBL4166749 | 0.64 | TSHR (0.53) | HTR2CTSHRPNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3469 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | claimed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | claimed |
| US-20200261421-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | claimed |
| US-20200069691-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-03-05 | — | — | US | claimed |
| EP-3558305-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3558285-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | claimed |
| WO-2018118827-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2018118829-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | claimed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | claimed |
| WO-1994002489-A1 | CEPHALOSPORINS AND 1-CARBA-1-DETHIA CEPHALOSPORINS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | claimed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | claimed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | claimed |
| US-4987130-A | ANTIARRHYTHMIA AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-22 | — | — | US | claimed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | claimed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | claimed |
| EP-0041674-B1 | 2-(TRICHLORO-METHYL-PHENYL)-4-HALOGEN-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-02-26 | — | — | EP | claimed |
| EP-0041675-B1 | 4-HALOGEN-5-(TRICHLOROMETHYL-PHENYL)-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-12-11 | — | — | EP | claimed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | claimed |